Profile data is unavailable for this security.
About the company
WuXi AppTec Co., Ltd. is a China-based investment holding company principally engaged in the provision of new drug research and development (R&D), production and supporting services, as well as related technology platform services. The Company is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. The Company mainly conducts its businesses through four segments, including China-based Laboratory Services segment, Contract Manufacturing organization/contract development and manufacturing organization services (CMO/CDMO services) segment, US-based Laboratory Services segment and Clinical Research segment.
- Revenue in CNY (TTM)39.36bn
- Net income in CNY9.38bn
- Incorporated2000
- Employees41.12k
- LocationWuXi AppTec Co Ltd228 Fute Zhong RoadWaigaoqiao Free Trade ZoneSHANGHAI 200131ChinaCHN
- Phone+86 2 150461000
- Fax+86 2 150463093
- Websitehttp://www.wuxiapptec.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical Co Ltd | 5.90bn | 4.39bn | 78.20bn | 2.09k | 17.81 | 15.17 | -- | 13.25 | 10.95 | 10.95 | 14.71 | 12.86 | 1.37 | 1.85 | 41.29 | 2,828,652.00 | 102.16 | -- | 138.88 | -- | 95.70 | -- | 74.42 | -- | 3.75 | 828.87 | 0.1314 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 3.38bn | 128.47m | 83.25bn | 3.84k | 703.46 | 6.48 | -- | 24.65 | 0.0933 | 0.0933 | 2.68 | 10.12 | 0.2058 | 0.8371 | 0.8434 | 878,660.70 | 0.7531 | 24.08 | 0.9228 | 31.80 | 76.97 | 85.18 | 3.66 | 34.95 | 3.84 | -- | 0.0258 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| WuXi AppTec Co Ltd | 39.36bn | 9.38bn | 114.90bn | 41.12k | 12.91 | 2.17 | -- | 2.92 | 3.18 | 3.18 | 13.33 | 18.97 | 0.55 | 4.33 | 4.93 | 957,267.30 | 13.24 | 11.76 | 16.74 | 15.00 | 40.08 | 38.46 | 24.07 | 21.69 | 1.95 | -- | 0.1124 | 30.01 | 2.51 | 33.22 | 9.00 | 33.56 | 19.66 | 32.04 |
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 21 Mar 2024 | 114.98m | 4.49% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 89.10m | 3.48% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 77.88m | 3.04% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 56.78m | 2.22% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 54.97m | 2.15% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 47.02m | 1.84% |
| China Asset Management Co., Ltd.as of 29 Feb 2024 | 36.07m | 1.41% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 35.37m | 1.38% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 32.74m | 1.28% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 26.04m | 1.02% |
